**Acknowledgements**

*Healthcare Access - Regional Overviews*

**Biologic agent Posology**

**Table 3.**

*Anti-IL-17 agents. Posology.*

**3. Biological therapies and pregnancy**

4 weeks afterwards

subsequently

administered once every month

**Therapeutic agent Contraception**

Despite their presently being no curative remedies for psoriasis, a wide assortment of specific molecular agents exist that are able to ameliorate the symptoms and produce remission. Delivering any of the aforementioned drugs varies primarily on the proficiency of the treating practitioner and only afterwards on the patient's personal choice. It is of utmost importance that women during childbearing age are aware that no studies have been conducted on whether or not these therapies are safe to use while pregnant. Consequently, should any of the biological treatments mentioned except for certolizumab be taken, they must be discontinued prior to conceiving a child. Considering certolizumab, as of writing this chapter, it is ostensibly the only discovered biological agent that fails to cross the maternal-placental barrier, and no adverse or teratogenic consequences were discovered if taken while pregnant [69]. In **Table 4**, we illustrate the minimal time interval suggested

Ixekizumab 80 mg × 2 at week 0 followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12 and at every

Secukinumab 150 mg × 2 at weeks 0, 1, 2, 3 and 4 and after the induction phase, 150 mg × 2 is

Brodalumab 210 mg × 1 at week 0, 1 and 2, followed by 210 mg × 1 administered every 2 weeks

Psoriasis is a debilitating disease with the potential to cause severe psychological damage. In spite of the plentiful advances vis-à-vis treatment, we are still a long way off from obtaining an actual cure. It is crucial to remember that current management strategies only address the symptoms, and not the cause. Therefore,

between discontinuing the medication and child conception [82].

Methotrexate During pregnancy and at least 3–6 months after

Adalimumab During pregnancy and minimum 5 months after

Ustekinumab During pregnancy and at least 15 weeks after Ixekizumab During pregnancy and at least 6 months after Secukinumab During pregnancy and minimum 20 weeks after

Cyclosporine Contraception only during the therapy Acitretin During pregnancy and at least 3 years after Fumaric acid esters During pregnancy and at least 2 weeks after Apremilast During pregnancy and 28 days after

Etanercept During pregnancy and 3 weeks after

**96**

**4. Conclusions**

*Systemic therapy and pregnancy interval.*

**Table 4.**

The authors would like to acknowledge the continuous support of Prof. Dr. Remus Orăsan.
